Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
about
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressantsBiochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.MMP mediated degradation of type VI collagen is highly associated with liver fibrosis--identification and validation of a novel biochemical marker assayPredictive and prognostic molecular markers for cancer medicineType VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young menHuman macrophage foam cells degrade atherosclerotic plaques through cathepsin K mediated processesBiochemical markers identify influences on bone and cartilage degradation in osteoarthritis--the effect of sex, Kellgren-Lawrence (KL) score, body mass index (BMI), oral salmon calcitonin (sCT) treatment and diurnal variation.Recent advances in cellular glycomic analyses.Distribution, size, shape, growth potential and extent of abdominal aortic calcified deposits predict mortality in postmenopausal women.Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats.The future of blood-based biomarkers for Alzheimer's disease.Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis.Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation.Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.Phosphodiesterase inhibition mediates matrix metalloproteinase activity and the level of collagen degradation fragments in a liver fibrosis ex vivo rat model.Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis.Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAsMeasurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachloride-induced fibrosis.Levels of Circulating MMCN-151, a Degradation Product of Mimecan, Reflect Pathological Extracellular Matrix Remodeling in Apolipoprotein E Knockout MiceAssessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis.Bone Mineral Content as a Driver of Energy Expenditure in Prepubertal and Early Pubertal Boys.Biomarkers in mood disorders research: developing new and improved therapeutics.Will posttranslational modifications of brain proteins provide novel serological markers for dementias?Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker.Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study.Atherofibrosis - a unique and common process of the disease pathogenesis of atherosclerosis and fibrosis - lessons for biomarker developmentApplication of biomarkers in the development of drugs intended for the treatment of osteoarthritisExtracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.A MMP derived versican neo-epitope is elevated in plasma from patients with atherosclerotic heart diseaseBiglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases.Tissue turnover of collagen type I, III and elastin is elevated in the PCLS model of IPF and can be restored back to vehicle levels using a phosphodiesterase inhibitor.Advances and challenges in hemophilic arthropathy.Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.Serological identification of fast progressors of structural damage with rheumatoid arthritis.Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.Post-translational modifications of the extracellular matrix are key events in cancer progression: opportunities for biochemical marker development.Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options.Molecular serum markers of liver fibrosis.
P2860
Q26996955-4A2F92A8-92AF-411B-AF99-5520D8B2749CQ27687777-E286BD75-D689-4284-B1E0-CB7A86A99D57Q28477074-65A79938-BE4B-43AA-9011-5CC01FF1F744Q28743108-7313E3C1-AAAF-485B-8573-1B80091690A6Q30557326-6E370649-3C24-418C-9A5E-F33D34C251D6Q33561251-3DC8886F-B661-4D26-B7A4-8161C3FAF242Q33610773-6D62E351-4331-4F5F-9EF9-9CEB4AA34E4EQ33649651-032D91F2-8DEF-45DE-B575-41AF21F07585Q33743650-921DAAD3-6F8E-417F-9630-CC9FBD952C0DQ33813357-A91194A0-0257-425A-B2C5-8D745AAE0444Q34026317-2E3B9C0C-0468-41AC-B425-DE6F9ED0918AQ34122276-542C06A9-FD93-4F4A-B091-7EDA6B23E768Q34346648-29B0A22B-F724-4E28-8D8B-652D22363BA5Q34373826-02DB19C1-DA22-408F-B637-3C47BE24EE8BQ34515203-02BACA4D-9F5D-47A8-A72D-77FCB86BD0EFQ34568353-AC13469A-093D-4E68-9486-9B30AAF313E0Q34785177-B29699DE-6D9D-4B97-B3BC-8BE4B2DD2159Q34788920-FFF590A0-DFBF-42A8-9AEF-5EA9AC406EFCQ35440249-579D0106-E4AD-4586-9A00-05175FC87D6FQ35477274-BFCD19B1-3B06-4FDB-AAD8-06F2860C1493Q35595130-8C2D3729-E959-4495-9C62-8D25CBFFAB6DQ35735694-A7E85F59-3ECC-4BE3-8868-A520FC69188BQ36072517-8D7E3EAF-B777-4107-B016-B105887F3241Q36251710-2427990E-5176-4D50-BBE2-28CE5BC5E2F1Q36367463-53BCED3D-4E5A-40A8-B3C1-1097B6940D5AQ36402230-66E799C3-E2E9-4B19-9956-527ADE585B1BQ36481786-C143E7CE-BBA6-40A9-9EF1-0D970C9C7391Q36576517-D6FB4E3F-7590-4EB4-B45D-2C29C29A5150Q36598469-B1BE5ECE-2D70-4FB8-88C2-22350A3E200BQ36672445-AC2CB4AD-A1D3-4B46-BAD8-B3D215425E0BQ36721004-9F5C0B23-2A64-47A5-974F-627339A0CA77Q36835374-1BC45A30-999A-4C57-BA5C-D5D721DD0754Q37089910-1BAB78BA-5BA3-4A5A-9B7E-AB334BEABBB5Q37279529-F9E6ABDF-32F2-43B3-9A80-529F2820A122Q37604322-085AE398-5FE8-493E-9C26-625FA459FD6DQ37689708-D58294F1-23A5-4EAF-AACA-E968D6A8CA43Q37775799-3726DE60-EE44-461E-A44D-797BF0DFE77BQ37867110-8E6D3427-5D44-426E-BA8F-D8A4A328DE39Q37951107-CE85597F-9839-43CA-9C06-09FEA98CF876Q38032835-D3C3D523-4081-4B96-A1F4-43BB84E839CE
P2860
Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biochemical markers and the FD ...... ry tools for drug development.
@en
Biochemical markers and the FD ...... ry tools for drug development.
@nl
type
label
Biochemical markers and the FD ...... ry tools for drug development.
@en
Biochemical markers and the FD ...... ry tools for drug development.
@nl
prefLabel
Biochemical markers and the FD ...... ry tools for drug development.
@en
Biochemical markers and the FD ...... ry tools for drug development.
@nl
P2093
P2860
P1433
P1476
Biochemical markers and the FD ...... ry tools for drug development.
@en
P2093
A C Bay-Jensen
C Christiansen
D J Leeming
I Byrjalsen
K Henriksen
L Klickstein
M A Karsdal
N Barascuk
P2860
P304
P356
10.1080/13547500902777608
P577
2009-05-01T00:00:00Z